Viracta Therapeutics, Inc. Announces Executive Changes
March 04, 2021 at 08:00 am
Share
Viracta Therapeutics, Inc. announced that it has strengthened its leadership team with the appointments of Drs. Stephen Rubino and Barry J. Simon to the Board of Directors, the addition of Cheryl A. Madsen, RAC as Senior Vice President, Regulatory Affairs, and the promotion of several members of the management team. In addition to the appointments of Ms. Madsen and Drs. Rubino and Simon, Viracta also announced the following management promotions, which are significant in the operations of Viracta as a publicly traded company: Dan Chevallard, formerly Chief Financial Officer, has been promoted to Chief Operating Officer and Chief Financial Officer. Shelly Vandertie, formerly Senior Director, Finance & Controller, has been promoted to Vice President, Finance. Michael Mueller, formerly Senior Director, Corporate Development & Legal Affairs, has been promoted to Vice President, Legal Affairs and General Counsel. Stephen Rubino, Ph.D., MBA has over 30 years of commercial and strategic development experience in the pharmaceutical and biotechnology industries. He is currently the Chief Business Officer at Celyad Oncology SA and sits on the Board of Sermonix Pharmaceuticals. Barry J. Simon, M.D., is a healthcare executive with more than 30 years of experience spanning the public and private sectors. He previously served on Viracta's board from July 2017 to November 2020 and is currently the President and Chief Administrative Officer (CAO) of Nantkwest, Inc. Cheryl A. Madsen, RAC brings over 25 years of regulatory affairs experience in the development of both biologics and small molecules ranging from pre-IND through commercial stage companies. Ms. Madsen joined Viracta Therapeutics from Calithera Biosciences where she served as Vice President of Regulatory Affairs.
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Companyâs lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.